Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
暂无分享,去创建一个
R. Kiessling | G. Parmiani | C. Castelli | L. Rivoltini | A. Mazzocchi | F. Rini | A. Ciupitu | G. Parmiani | Rolf Kiessling
[1] Stuart K. Calderwood,et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.
[2] G. Parmiani,et al. T‐cell recognition of melanoma‐associated antigens , 2000 .
[3] Nina Bhardwaj,et al. Consequences of cell death: exposure to necrotic tumor cells , 2000 .
[4] R. Jensen,et al. Protein translocation: Is Hsp70 pulling my chain? , 1999, Current Biology.
[5] R. Schekman,et al. Protein Translocation How Hsp70 Pulls It Off , 1999, Cell.
[6] B. Fleischer,et al. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. , 1999, Journal of immunology.
[7] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[8] H. Rammensee,et al. Stress proteins and immunity mediated by cytotoxic T lymphocytes. , 1999, Current opinion in immunology.
[9] G. Parmiani,et al. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. , 1999, Journal of immunology.
[10] P. Srivastava,et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. , 1999, Journal of immunology.
[11] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[12] M. Lotze,et al. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. , 1998, Journal of immunology.
[13] P. Srivastava,et al. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. , 1998, Immunity.
[14] A. Melcher,et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression , 1998, Nature Medicine.
[15] M. Maio,et al. Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients , 1998, European journal of immunology.
[16] R. Welsh,et al. Immunization with a Lymphocytic Choriomeningitis Virus Peptide Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.
[17] P. Srivastava,et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.
[18] P. Srivastava,et al. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. , 1997, Journal of immunological methods.
[19] P. Srivastava,et al. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.
[20] H. Rammensee,et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.
[21] J. Sambrook,et al. Common and divergent peptide binding specificities of hsp70 molecular chaperones. , 1994, The Journal of biological chemistry.
[22] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[23] G. Parmiani,et al. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. , 1993, Immunology today.